Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.
Relmada Therapeutics, Neoleukin Therapeutics, and Durect were among the fastest-rising pharmaceutical stocks over the past year.
No podcast episodes available.
DRRX earnings call for the period ending September 30, 2020.
DRRX earnings call for the period ending June 30, 2020.
DRRX earnings call for the period ending March 31, 2020.
DRRX earnings call for the period ending December 31, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.